Investigations could hurt Ranbaxys ANDAs filed in US (Express India)
Although Ranbaxy has ruled out any possible impact on its US operations owing to the recent federal investigations, the company is likely to be hurt if the US FDA, the medical regulatory authority in the US, asks it to re-submit the ANDA for generic drugs which are awaiting approvals in the US.

FDA comes under Congress scanner over Ranbaxy issue (The Times of India)
The US drug regulator FDA, which has charged Ranbaxy of selling unsafe medicines in the country, has come under the parliamentary scanner.